Latest News

Preliminary year-end results May 14 2013: announcement and presentation

 
-
The Network Pharmacology Company
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.  

It has a clinical pipeline of two drugs, ETS2101, which is in phase I trials for cancer, and ETS6103, which is in phase II development for depression

 

e-Therapeutics is listed on AIM with the ticker symbol ETX

 
David Cameron at eTherapeutics
British Prime Minister David Cameron and Prof. Malcolm Young, CEO of e-Therapeutics, shake hands as the Prime Minister opens our drug discovery centre at Oxford. more
e-Therapeutics to raise £40m
See the press release and circular for shareholders
 
ETS2101 solid tumour trial
e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101.

The full article can be read here.


 
Latest corporate presentation
Latest corporate presentation PDF